Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
| Revenue (Most Recent Fiscal Year) | $76.99M |
| Net Income (Most Recent Fiscal Year) | $-174.57M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.47 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.46 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -53.52% |
| Net Margin (Trailing 12 Months) | -53.52% |
| Return on Equity (Trailing 12 Months) | -31.37% |
| Return on Assets (Trailing 12 Months) | -16.01% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.87 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.79 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.46 |
| Inventory Turnover (Trailing 12 Months) | 0.08 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.02 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.27 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 638.02M |
| Free Float | 590.68M |
| Market Capitalization | $899.60M |
| Average Volume (Last 20 Days) | 10.57M |
| Beta (Past 60 Months) | 0.73 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.42% |
| Percentage Held By Institutions (Latest 13F Reports) | 73.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |